Eganelisib

Small moleculeexperimental

Chemistry & pharmacology

Loading structure…

SMILES

C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cnn(C)c3)c2c(=O)n1-c1ccccc1
Mol. weight
528.58 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • ipi-549
  • ipi-549

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03795610Phase 2Jun 30, 2019University of California, San Diego, V Foundation
NCT03980041Phase 2Jun 30, 2019Bristol-Myers Squibb, Infinity Pharmaceuticals, Inc.
NCT03961698Phase 2Jun 1, 2019Infinity Pharmaceuticals, Inc., Roche
NCT03719326Phase 1Oct 15, 2018Arcus Biosciences, Inc., Infinity Pharmaceuticals, Inc.
NCT02637531Phase 1Dec 1, 2015Infinity Pharmaceuticals, Inc.
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Infinity Pharmaceuticals, Inc.For profit4322015
Arcus Biosciences, Inc.For profit1112018
Bristol-Myers SquibbFor profit1012019
RocheFor profit1012019
University of California, San DiegoAcademic/Hospital1112019
V FoundationAcademic/Hospital1012019
6 organizations
Page 1 / 1